专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

111. 发明公开

EP2351756A1 SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-A]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS AND METHODS FOR THE PRODUCTION AND USE THEREOF 审中-公开
标题翻译：取代的3-芳基磺酰基 - 吡唑并[1,5-A]嘧啶，血清素5-HT6受体拮抗剂和方法的生产和使用
公开(公告)号：EP2351756A1
公开(公告)日：2011-08-03
申请号：EP09819452.5
申请日：2009-10-06
申请人： Ivashchenko, Andrey Alexandrovich , Alla Chem, LLC.
发明人： IVASHCHENKO, Alexander Vasilievich , SAVCHUK Nikolay Filippovich , LAVROVSKY Yan , MITKIN, Oleg Dmitrievich , KADIEVA Madina Georgievna
IPC分类号： C07D487/04 , A61K31/519 , A61P25/28 , A61P25/18 , A61P25/26 , A61P25/16 , A61P25/08 , A61P9/10 , A61P3/04 , A61P3/08 , A61K9/48 , A61K9/08
CPC分类号： C07D487/04
摘要： The invention relates to the novel substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines of the general formula 1, pharmaceutically acceptable salts and/or hydrates thereof, serotonin 5-HT 6 receptor antagonists and pharmaceutical compositions, and also to method for prophylaxis and treatment of various diseases of central nervous system at humans and warm-blooded animals pathogenesis of which is associated with serotonin 5-HT 6 receptors, in particular, Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, and other neurodegenerative diseases, cognitive disorders and obesity.
In the general formula 1:

wherein: X = S, SO or NH; R 1 represents hydrogen, optionally substituted C 1 -C 3 alkyl, cycloalkyl, adamantyl, aryl or heterocyclyl; R 2 represents hydrogen, halogen, optionally substituted C 1 -C 3 alkyl, substituted hydroxyl, aryldiazenyl or optionally substituted amino group; R 3 represents hydrogen, optionally substituted C 1 -C 3 alkyl, substituted hydroxyl, pyridyl or optionally substituted amino group, besides, in cases when X = S or X = NH, at least one of R 1 , R 2 or R 3 represent substituted C 1 -C 3 alkyl, cycloalkyl, adamantyl, aryl, heterocyclyl, halogen, substituted hydroxyl, optionally substituted amino group, aryldiazenyl, or at least two of R 1 , R 2 or R 3 represent hydrogen; R 4 represents C 1 -C 3 alkyl; R 5 represents hydrogen, one or two halogens, C 1 -C 3 alkyl or optionally substituted hydroxyl.
摘要翻译：本发明涉及新颖的substituiertem 3-芳基磺酰基 - 吡唑并[1,5-A]通式1的嘧啶，其药学上可接受的盐和/或水合物，五羟色胺5-HT 6受体拮抗剂和药物组合物，并且因此方法用于特别是在人类和温血动物的所有发病预防和治疗中枢神经系统的各种疾病的，其与血清素5-HT 6个受体相关的疾病，阿尔茨海默氏症，帕金森氏病，亨廷顿氏病，精神分裂症，以及其它神经变性疾病，认知障碍和肥胖。在通式1：其中：X = S，SO或NH; 的R 1 darstellt氢，任选取代的C 1 -C 3烷基，环烷基，金刚烷基，芳基或杂环基; R 2 darstellt氢，卤素，任选取代的C 1 -C 3烷基，取代的羟基，或aryldiazenyl任选取代的氨基; ，R 3 darstellt氢，任选取代的C 1 -C 3烷基，取代的羟基，吡啶基或任选取代的氨基基团，此外，在情况下，当X = S或X = NH，R 1，R中的至少一个2或R 3代表取代的C 1 -C 3烷基，环烷基，金刚烷基，芳基，杂环基，卤素，取代的羟基，任选取代的氨基，aryldiazenyl，或至少两个R 1，R 2或R 3表示氢; ，R 4 darstellt C 1 -C 3烷基; 的R 5 darstellt氢，一个或两个卤素，C 1 -C 3烷基或任意取代的羟基。

112. 发明公开

EP2342977A2 Composition for improving membrane composition and functioning of cells 审中-公开
标题翻译： Zusammensetzung zur Verbesserung der Membranzusammensetzung und Zellfunktion
公开(公告)号：EP2342977A2
公开(公告)日：2011-07-13
申请号：EP11157517.1
申请日：2006-12-22
申请人： N.V. Nutricia
发明人： Hageman, Robert Johan Joseph
IPC分类号： A23L1/29 , A23L1/30 , A23L1/305 , A23L1/304 , A61K31/202 , A61K31/198 , A61K31/185 , A61K31/7052 , A61K33/32 , A61K33/24 , A61P3/04 , A61P3/08 , A61P3/10
CPC分类号： A61K31/202 , A23L33/12 , A23L33/15 , A23L33/16 , A23L33/17 , A23L33/40 , A23V2002/00 , A61K31/185 , A61K31/198 , A61K31/20 , A61K33/24 , A61K33/32 , A61K35/20 , A61K45/06 , A61K2300/00 , A23V2250/161 , A23V2250/1608 , A23V2250/302 , A23V2250/28 , A23V2250/70 , A23V2250/72 , A23V2250/705 , A23V2250/54252 , A23V2250/54246 , A23V2250/194 , A23V2200/332 , A23V2250/5488 , A23V2250/061 , A23V2250/0624 , A23V2250/1868 , A23V2250/187 , A23V2250/0616 , A23V2250/1618 , A23V2250/7052 , A23V2250/7056 , A23V2250/706 , A23V2250/1612 , A23V2250/5114 , A23V2250/628 , A23V2250/712 , A23V2250/708 , A23V2250/1626 , A23V2250/1642 , A23V2250/714 , A23V2200/328 , A23V2250/548 , A23V2250/608 , A23V2250/62 , A23V2250/5118 , A23V2250/5108 , A23V2250/218 , A23V2250/156 , A23V2200/304 , A23V2250/0644 , A23V2250/304 , A23V2250/1842
摘要： It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises
a/ a lipid fraction comprising at least one of docosahexaneoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA);
b/ a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and
c/ a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.
摘要翻译：现在已经发现，在给患有发展这种疾病的危险的患病个体或个人之后，该药物或药物组合物包含包含二十二碳六烯酸（DHA），二十二碳五烯酸（DPA）中的至少一种的脂质部分）和二十碳五烯酸（EPA）; b / a包含提供至少半胱氨酸和/或牛磺酸的来自非人源的蛋白质物质的蛋白质级分; 和c / a包含锰和钼中的至少一种的矿物部分，这些人的健康状况改善。几种类型的哺乳动物细胞的膜功能改善，其允许有效治疗免疫相关疾病，例如过敏，自身免疫疾病，癌症，认知功能障碍和其他神经系统疾病，神经病，如糖尿病性神经病和神经性疼痛，神经元损伤在胰岛素抵抗期间，肠道疾病和支持生长或恢复期间肠和肺功能的发展。

113. 发明公开

EP2168588A4 AN EXTRACT OF REHMANNIA GLUTINASA LIBOSCH. FOR REDUCING BLOOD SUGAR, REDUCING BLOOD FAT, TREATING LEUKEMIA AND PREPARATION METHOD AND USES THEREOF 有权
标题翻译：提取熟地GLUTINASA地黄。降低血糖，TO降低血脂，白血病的治疗和方法及用途
公开(公告)号：EP2168588A4
公开(公告)日：2011-07-06
申请号：EP08772995
申请日：2008-06-27
申请人： ZHANG LING
发明人： ZHANG LING
IPC分类号： A61K36/804 , A61P3/06 , A61P3/08 , A61P7/00 , A61P35/02
CPC分类号： A61K36/804 , A61K31/7048 , B01D15/08 , G01N30/02
摘要： The present invention relates to a Rehmannia glutinasa Libosch. extract for reducing blood glucose and lipid levels and treating hematologic diseases such as leukemia, and methods for preparing the same. The extract is prepared by subjecting fresh Rehmannia glutinasa Libosch. to flux extraction, concentrating the resultant extract, dissolving the concentrated extract with water, loading the obtained solution on a column packed with macroporous adsorption resins, eluting the column with ethanol, concentrating and drying the eluate. The extract can be made into clinically acceptable forms of dosage by pharmaceutically conventional measures, including capsule, tablet, pill, granule, dropping pill and so on. The extract is stable and has catalpol content up to 90-98%. The preparing method is simple to operate and applicable to industrial-scale production.

114. 发明公开

EP2303040A1 SYNERGISTIC ENHANCEMENT OF CELLULAR ERGOGENIC NUTRIENT UPTAKE, LIKE CREATINE OR CARNITINE, WITH TARRAGON 审中-公开
标题翻译：协同PROMOTE基因ERGO的营养，如肌酸或肉碱，列入通过细胞爱斯特拉冈手段
公开(公告)号：EP2303040A1
公开(公告)日：2011-04-06
申请号：EP09757610.2
申请日：2009-06-05
申请人： PhytoLab GmbH & Co. KG
发明人： JAEGER, Ralf , PURPURA, Martin , PISCHEL, Ivo
IPC分类号： A23L2/52 , A61K31/198 , A61K31/205 , A61K36/282 , A61P3/02 , A61P3/08 , A61P21/06
CPC分类号： A61K36/282 , A23L2/52 , A23L33/105 , A23L33/175 , A23L33/40 , A23V2002/00 , A61K31/198 , A61K31/205 , A61K2300/00 , A23V2250/704 , A23V2250/708 , A23V2250/712 , A23V2250/1578 , A23V2250/161 , A23V2250/1642 , A23V2250/21 , A23V2250/0612 , A23V2250/306
摘要： A product comprising a) Russian Tarragon (Artemisia dracunculus), an extract of Russian Tarragon or a derivative thereof b) a creatine and/or carnitine compound or derivative or precursor thereof.

115. 发明公开

EP2294932A1 CARBOHYDRATE MIXTURE AND THE USE THEREOF FOR PREPARING A PRODUCT FOR ORAL OR ENTERAL NUTRITION 有权
标题翻译：碳水化合物MIX和他们对产品的生产使用口服或肠内营养
公开(公告)号：EP2294932A1
公开(公告)日：2011-03-16
申请号：EP08761564.7
申请日：2008-05-07
申请人： Vegenat, S.A.
发明人： GIL HERNANDEZ, Ángel , SAN ROMÁN PAIS, Paloma , PEREZ RODRIGUEZ, Milagros
IPC分类号： A23L1/29 , A61K31/718 , A61P3/08 , A61P3/02
CPC分类号： A61K31/718 , A23L29/212 , A23L29/35 , A23L33/21 , A23L33/40
摘要： The present invention is related to a new mixture of carbohydrates and its usage for the preparation of a food product intended for oral or enteral nutrition, particularly for the nutrition of the diabetic patient and in particular for the nutrition of the diabetes type. II patient and their associated comorbidity. The carbohydrate mixture of the present invention is formed by type IV or RS IV (modified maltodextrine) resistant starch, maltodextrin of low dextrose equivalent DE = 5-8, preferably DE equal to 6, inulin and cellulose and is exempt from fructose.
摘要翻译：本发明涉及碳水化合物的新的混合物及其用于口服或肠内营养，特别是对于糖尿病患者的营养和尤其是用于糖尿病类型的营养食品产品的制备使用情况。 II病人及其相关的合并症。本发明的碳水化合物混合物通过IV或IV RS类型FORMED（改性麦芽糖糊精）的抗性淀粉，低葡萄糖当量DE = 5-8，优选DE等于6，菊糖和纤维素的麦芽糖糊精和来自果糖免除。

116. 发明公开

EP2282768A1 ANTI-HMGA1 MONOCLONAL ANTIBODIES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE QUANTITATIVE DETERMINATION OF HMGA1 有权
标题翻译：单克隆抗HMGA1-抗体，其制造方法相同，它们用于HMGA1的定量测定
公开(公告)号：EP2282768A1
公开(公告)日：2011-02-16
申请号：EP09738465.5
申请日：2009-04-29
申请人： Areta International S.r.l.
发明人： FUSCO, Alfredo , ORLANDI, Antonio , NOLLI, Maria Luisa
IPC分类号： A61K39/00 , C07K16/18 , A61P3/08
CPC分类号： A61K39/0008 , A61K2039/5256 , C07K16/24 , C12N2710/10022
摘要： This invention concerns a panel of monoclonal antibodies against the High Mobility Group A 1 protein (HMGAl) and a process for preparing them, as well as the use of said antibodies for the quantitative determination of HMGAl in biological fluids or in protein Iy sates deriving from lymphocyte cells. This invention also concerns a diagnostic kit for assessing risk factors related to the expression of the HMGAl proteins.

117. 发明公开

EP2240182A1 TREATING HYPERGLYCEMIA WITH 25-HYDROXYVITAMIN D3 有权
标题翻译：高血糖与25-羟基维生素D3和维生素D治疗
公开(公告)号：EP2240182A1
公开(公告)日：2010-10-20
申请号：EP09710362.6
申请日：2009-02-12
申请人： DSM IP Assets B.V.
发明人： BUCK, Neil, Robert , LEUENBERGER, Bruno, H. , STOECKLIN, Elisabeth , URBAN, Kai , WOLFRAM, Swen , CLAERHOUT, Wouter
IPC分类号： A61K31/593 , A61P3/08 , A61P3/10
CPC分类号： A61K31/593 , A23L33/155 , A23V2002/00 , A61K31/59 , A61K2300/00 , A23V2200/326 , A23V2250/71
摘要： We disclose treating hyperglycemia in a human with 25-hydroxyvitamin D3 (calcifediol). Blood glucose is reduced to a level which is closer to normal than baseline. Vitamin D3 (cholecalciferol) may optionally be used together with 25-hydroxy vitamin D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed.

118. 发明公开

EP2231197A2 METHODS OF GENERATING EXPANDED AND RE-DIFFERENTIATED ADULT ISLET BETA CELLS FOR USE IN THE TREATMENT OF DIABETES 审中-公开
标题翻译：一种生产再分化扩大和成人胰岛β细胞在糖尿病治疗过程中使用
公开(公告)号：EP2231197A2
公开(公告)日：2010-09-29
申请号：EP08862277.4
申请日：2008-12-16
申请人： Ramot at Tel-Aviv University Ltd.
发明人： EFRAT, Shimon , BAR, Yael
IPC分类号： A61K48/00 , A61P3/08 , A61P5/50
CPC分类号： C12N5/0676 , A61K35/00 , C12N5/0678 , C12N15/113 , C12N2310/14 , C12N2330/51 , C12N2501/42 , C12N2506/22
摘要： A method of increasing insulin content in adult islet beta cells is disclosed. The method comprises contacting the adult islet beta cells with an agent capable of down-regulating activity and/or expression of at least one component participating in a NOTCH pathway, the component being up-regulated in beta cell dedifferentiation above a predetermined threshold, thereby increasing the insulin content in adult islet beta cells. Methods of labeling dedifferentiated adult islet beta cells are also disclosed. Cell populations generated using the methods of the present invention and uses thereof are also disclosed.

119. 发明公开

EP2218721A1 Novel salts of sitagliptin 审中-公开
标题翻译： Neuartige Salze von Sitagliptin
公开(公告)号：EP2218721A1
公开(公告)日：2010-08-18
申请号：EP09152526.1
申请日：2009-02-11
申请人： LEK Pharmaceuticals d.d.
发明人： The designation of the inventor has not yet been filed
IPC分类号： C07D487/04 , A61K31/4985 , A61P3/08
CPC分类号： C07D487/04
摘要： The present invention relates to novel pharmaceutically acceptable salts of sitagliptin, to processes for their preparation and to pharmaceutical compositions containing them.
摘要翻译：本发明涉及西格列汀的新型药学上可接受的盐，其制备方法和含有它们的药物组合物。

120. 发明公开

EP2197432A1 USE OF DIAZOXIDE FOR SUPPRESSING THE PLASMA INSULIN LEVEL IN A MAMMAL 审中-公开
标题翻译：二氮嗪血浆胰岛素镜子在哺乳动物中使用还原
公开(公告)号：EP2197432A1
公开(公告)日：2010-06-23
申请号：EP08835296.8
申请日：2008-10-02
申请人： Coöperatieve Mirzorg U.A., Arnhem
发明人： DE BOER, Johannes Mathijs Maria
IPC分类号： A61K31/00 , A61K31/549 , A61P3/08
CPC分类号： A61K31/00 , A61K31/549
摘要： The present invention relates to the use of a potassium channel activator in the manufacture of a medicament for suppressing the fasting plasma insulin leveland/or postabsorptive insulin level in a mammal in need thereof, wherein the fasting and/or postabsorptive plasma insulin level is reduced to about 5 mU/1 or less. The present invention also relates to the use ofa potassium channel activator in the manufacture of a medicament for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof for treating or preventing obesity, obesity related disorders and conditions and other disorders and conditions related to weight gain in a mammal in need thereof,said method comprising orally administering to said mammal in need thereofa daily dosage of about 5 mg to about 1200 mg, calculated on a Diazoxide active weight basis.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式